Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCTAVE-DUO COVID-19 revaccination trial in immunocompromised adults
ISRCTN15354495Phase 3Completed
- Sponsor
- University of Birmingham
- Start
- Jul 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of tozinameran, elasomeran and NVX-CoV2373 in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by University of Birmingham. Primary endpoints: Change in anti-spike SARS-CoV-2 antibody response at day 21 after re-boost and Change in SARS-CoV-2-specific T-cell response at day 21 after re-boost. Started Jul 2021; status: completed.
02
Drugs
tozinameranelasomeranNVX-CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN15354495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15354495.